Our Company
Eleanor N. Fish, CM, PhD, FAAS
Founder & President
Member, Order of Canada
Professor, Immunology, University of Toronto
Associate Chair, International Collaborations & Initiatives, Immunology, University of Toronto
Professor, Pediatrics, University of Toronto
Emerita Scientist, Toronto General Hospital Research Inst., University Health Network
Fellow, American Academy of Microbiology
Fellow, African Academy of Sciences
Tier 1 Canada Research Chair in Women’s Health & Immunobiology
Member, Expert Scientific Panel to Chief Scientific Advisor, Government of Canada
Member, Government of Canada COVID-19 Therapeutics Task Force
MANAGEMENT
Ramtin Rahbar, PhD
Senior CMC Advisor
Dr. Rahbar is a distinguished senior executive in the field of bio-therapeutic manufacturing, internationally recognized as a leading expert in cutting-edge biomanufacturing technologies. With over 18 years of experience, he has demonstrated excellence in people management, process development, technology transfer, clinical manufacturing, and regulatory filing for biologics CMC. His career is underscored by a notable track record of scientific research, marked by the publication of 35 peer-reviewed articles. Dr. Rahbar’s contributions highlight his commitment to advancing biomanufacturing technologies, establishing him as a leader in the intricacies of bio-therapeutic manufacturing.
ADVISORY BOARD
Ali Tehrani, PhD
Strategic Advisor
Dr. Tehrani is a partner at Amplitude VC which is a Canadian Venture Capital investment firm with offices in Montreal,
Toronto and Vancouver. Dr. Tehrani is a co-founder of Zymeworks and served as President and Chief Executive
Officer, and as a member of the Board of Directors, from the company’s inception in September 2003 to January
2022.
He led the company through many key corporate achievements including the development of multiple protein
engineering platforms, initial public offering on the New York Stock Exchange in 2017, establishing 9 partnerships with
major Pharma and Biotech companies, advancing two internal multi-specific antibody therapeutics into clinical trials
and the initiation of a global Phase 3 study for the lead program.
Dr. Tehrani holds both Bachelor’s and Master’s of Science degrees in biochemistry from the University of
Massachusetts, and has a Doctoral degree in microbiology and Immunology from the University of British Columbia.
In 2021 and 2022 he was named as one of British Columbia’s Top 500 Influential Business Leaders by Business in
Vancouver.
Dr. Tehrani is a member of the Board of Directors at Creatus Biosciences Inc. , QurCan, BIOTECanada, and the
Canada’s National Research Council. In the past he has served on the boards of CQDM, LifeSciences British
Columbia, and the MITACS industrial advisory. He was also a member of British Columbia’s Premier’s Technology
Council from 2016 to 2018.